Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

Who Took Part

The abstract describes 106 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, women only.

Post-hoc exploratory analysis were performed for patients with and without baseline nocturnal polyuria (NP, n = 47 each).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

Primary endpoint was change from baseline in mean number of nocturnal voids.

Secondary endpoints were change from baseline in nocturnal voided volume, time to first nocturnal void, and quality-of-life.

What Was Measured

PubMed files the paper under topics including Antidiuretic Agents, Deamino Arginine Vasopressin, Drug Combinations, Nocturia, Proof of Concept Study, Quality of Life and Tolterodine Tartrate.

Author keywords: antimuscarinics, desmopressin and overactive bladder.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 106 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Lower urinary tract symptoms), a journal based in Australia.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.